The Institute was proposing that the review of NICE Technology Appraisal Guidance No. 29 Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia be deferred to allow the results of the current MRC trial CLL4 to inform the review.

During consultation, all of comments received by the Institute agreed with the proposal put forward. 

The Institute’s Guidance Executive has decided to proceed with the proposal.

We will therefore contact consultees and commentators during August 2005 for consultation on a draft scope for this review.